Compare SSTK & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSTK | LXEO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.2M | 731.3M |
| IPO Year | 2012 | 2023 |
| Metric | SSTK | LXEO |
|---|---|---|
| Price | $19.40 | $7.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $25.00 | $18.60 |
| AVG Volume (30 Days) | 179.5K | ★ 1.3M |
| Earning Date | 02-24-2026 | 11-05-2025 |
| Dividend Yield | ★ 6.83% | N/A |
| EPS Growth | ★ 66.87 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $1,020,010,000.00 | N/A |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.48 | ★ N/A |
| Revenue Growth | ★ 13.06 | N/A |
| 52 Week Low | $14.35 | $1.45 |
| 52 Week High | $32.00 | $10.99 |
| Indicator | SSTK | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 38.55 |
| Support Level | $17.95 | $7.02 |
| Resistance Level | $19.09 | $7.84 |
| Average True Range (ATR) | 0.65 | 0.81 |
| MACD | 0.11 | -0.19 |
| Stochastic Oscillator | 82.75 | 15.58 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.